SCHEMBL1776465

SCHEMBL1776465

C/C(=N/c1c(C)cccc1C(C)C)c1cccc(/C(C)=N\c2c(C)cccc2C(C)C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
LMNA P02545 3/20 0.36
GABRB2 P47870 2/20 0.36
TSHR P16473 2/20 0.36
CYP1A2 P05177 2/20 0.36
FAAH O00519 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
GABRB1 P18505 1/20 0.36
PTGS1 P23219 1/20 0.36
SLC6A2 P23975 1/20 0.36
HTR2C P28335 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
HTR2B P41595 1/20 0.36
GABRA2 P47869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1776466 1.00 GABRA1 (0.37) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL8091210 1.00 GABRA1 (0.37) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL5587461 0.98 GABRA1 (0.36) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL18543889 0.95 GABRA1 (0.36) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL6906013 0.95 GABRA1 (0.36) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL2566362 0.93 CTSA (0.33) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL2566357 0.93 CTSA (0.33) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL12266367 0.92 SIGMAR1 (0.39) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL2564389 0.92 SIGMAR1 (0.39) GABRA1GABRG2GABRB3LMNAGABRB2
SCHEMBL2564391 0.92 SIGMAR1 (0.39) GABRA1GABRG2GABRB3LMNAGABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943715-B2 Polymerization of 1,6-heptadiene in the presence of a catalyst formed by contacting a transition metal with a diimino aluminum or boron compound, giving a polymer structure of alternating ethylene and cyclopentene; superior balance between a heat resistance and workability SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-20080221286-A1 DIENE POLYMER AND PROCESS FOR PRODUCING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-09-11 US disclosed
US-20080021180-A1 CHROMIUM CATALYSTS ACTIVE IN OLEFIN POLYMERIZATION REPSOL QUIMICA, S.A. 2008-01-24 US disclosed
EP-1325924-B1 Chromium catalysts active in olefin polymerisation REPSOL QUIMICA SA (ES) 2005-03-16 EP disclosed
US-20040087434-A1 Chromium catalysts active in olefin polymerization REPSOL QUIMICA, S.A. (ES) 2004-05-06 US disclosed
EP-1325924-A1 Chromium catalysts active in olefin polymerisation REPSOL QUIMICA S.A. (ES) 2003-07-09 EP disclosed
EP-1325925-A1 Chromium catalysts active in olefin polymerization REPSOL QUIMICA S.A. (ES) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087434-A1 Chromium catalysts active in olefin polymerization CBR1, SCO2, CBR3 GABRA1 4149/4885GABRG2 4606/4885GABRB3 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.